Segall Bryant & Hamill’s Editas Medicine EDIT Stock Holding History

Segall Bryant & Hamill’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,058	Closed	-$289K	–	628
2021 Q3	$289K	Hold	7,058	–	–	﹤0.01%	700
2021 Q2	$400K	Sell	7,058 -148,681	-95%	-$5.49M	﹤0.01%	651
2021 Q1	$6.55M	Sell	155,739 -60	-0%	-$3.42K	0.06%	280
2020 Q4	$10.9M	Sell	155,799 -99,750	-39%	-$4.1M	0.12%	185
2020 Q3	$7.17M	Buy	255,549 +11,549	+5%	+$376K	0.1%	208
2020 Q2	$7.22M	Sell	244,000 -5,550	-2%	-$145K	0.12%	173
2020 Q1	$4.96M	Sell	249,550 -3,900	-2%	-$98.4K	0.1%	194
2019 Q4	$7.5M	Sell	253,450 -3,750	-1%	-$93.7K	0.12%	181
2019 Q3	$5.85M	Sell	257,200 -13,550	-5%	-$336K	0.09%	249
2019 Q2	$6.7M	Sell	270,750 -200	-0.1%	-$4.77K	0.1%	229
2019 Q1	$6.62M	Buy	+270,950	New	+$6.13M	0.1%	235

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Segall Bryant & Hamill's EDIT Position: Q4 2021 in Review

Segall Bryant & Hamill sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 7,058 shares — an estimated $289K sold.

Segall Bryant & Hamill first reported a position in EDIT in Q1 2019 and held it in 11 quarters. The position peaked at $10.9M in Q4 2020. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

Segall Bryant & Hamill reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
Segall Bryant & Hamill sold 7,058 Editas Medicine shares in Q4 2021, an estimated $289K.
Segall Bryant & Hamill first reported a position in Editas Medicine in Q1 2019 and held it in 11 quarters.
Segall Bryant & Hamill's Editas Medicine position peaked at $10.9M in Q4 2020.
305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Segall Bryant & Hamill's 13F filing for Q4 2021, filed 14 Feb 2022.